Last reviewed · How we verify

Arthritic Pain — Treatment Landscape & Competitive Intelligence

Arthritic Pain (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Arthritic Pain, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Qutenza CAPSAICIN Averitas capsaicin Transient receptor potential cation channel subfamily V member 1 2009-01-01
Salonpas METHYL SALICYLATE Hisamitsu Pharm Co methyl salicylate 2008-01-01
Acetaminophen Paracetamol Polymedica acetaminophen Transient receptor potential cation channel subfamily V member 4 1968-01-01
Norgesic acetylsalicylic acid Endo centrally acting muscle relaxant with anticholinergic properties reticular formation (brain stem) 1950-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 2 drugs in Arthritic Pain
  2. Averitas · 1 drug in Arthritic Pain
  3. Endo · 1 drug in Arthritic Pain
  4. Hisamitsu Pharm Co · 1 drug in Arthritic Pain
  5. Polymedica · 1 drug in Arthritic Pain

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Arthritic Pain:

Cite this brief

Drug Landscape (2026). Arthritic Pain — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/arthritic-pain. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing